These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 29157617

  • 1. The Role of Interleukin-6 in Castleman Disease.
    Yoshizaki K, Murayama S, Ito H, Koga T.
    Hematol Oncol Clin North Am; 2018 Feb; 32(1):23-36. PubMed ID: 29157617
    [Abstract] [Full Text] [Related]

  • 2. [Tocilizumab treatment of HHV8-positive/HIV-negative, multricentric plasma cell type Castleman's disease].
    Mûzes G, Csomor J, Sipos F.
    Magy Onkol; 2016 Nov 29; 60(4):328-332. PubMed ID: 27898752
    [Abstract] [Full Text] [Related]

  • 3. Treatment of Idiopathic Castleman Disease.
    van Rhee F, Greenway A, Stone K.
    Hematol Oncol Clin North Am; 2018 Feb 29; 32(1):89-106. PubMed ID: 29157622
    [Abstract] [Full Text] [Related]

  • 4. Reversible cardiomyopathy associated with Multicentric Castleman disease: successful treatment with tocilizumab, an anti-interleukin 6 receptor antibody.
    Kanda J, Kawabata H, Yamaji Y, Ichinohe T, Ishikawa T, Tamura T, Furukawa Y, Kimura T, Kita T, Uchiyama T.
    Int J Hematol; 2007 Apr 29; 85(3):207-11. PubMed ID: 17483056
    [Abstract] [Full Text] [Related]

  • 5. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.
    Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T.
    Blood; 2008 Nov 15; 112(10):3959-64. PubMed ID: 18784373
    [Abstract] [Full Text] [Related]

  • 6. The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease.
    Sun Y, Wang D, Salvadore G, Hsu B, Curran M, Casper C, Vermeulen J, Kent JM, Singh J, Drevets WC, Wittenberg GM, Chen G.
    Brain Behav Immun; 2017 Nov 15; 66():156-164. PubMed ID: 28676350
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease.
    Song SN, Tomosugi N, Kawabata H, Ishikawa T, Nishikawa T, Yoshizaki K.
    Blood; 2010 Nov 04; 116(18):3627-34. PubMed ID: 20644113
    [Abstract] [Full Text] [Related]

  • 9. [Evans syndrome complicated with multicentric Castleman disease successfully treated with tocilizumab].
    Nakayama H, Kikuchi T, Abe R, Tozawa K, Watanuki S, Shimizu T, Mitsuhashi T, Murata M, Okamoto S, Mori T.
    Rinsho Ketsueki; 2018 Nov 04; 59(8):997-1001. PubMed ID: 30185717
    [Abstract] [Full Text] [Related]

  • 10. Is tocilizumab a potential therapeutic option for refractory unicentric Castleman disease?
    Abid MB, Peck R, Abid MA, Al-Sakkaf W, Zhang Y, Dunnill GS, Staines K, Sequeiros IM, Lowry L.
    Hematol Oncol; 2018 Feb 04; 36(1):320-323. PubMed ID: 28401573
    [Abstract] [Full Text] [Related]

  • 11. Clinicopathologic characteristics of 342 patients with multicentric Castleman disease in Japan.
    Murakami M, Johkoh T, Hayashi S, Ohshima S, Mizuki M, Nakatsuka SI, Tomobe M, Kuroyanagi K, Nakasone A, Nishimoto N.
    Mod Rheumatol; 2020 Sep 04; 30(5):843-851. PubMed ID: 31829070
    [Abstract] [Full Text] [Related]

  • 12. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease.
    Kawabata H, Tomosugi N, Kanda J, Tanaka Y, Yoshizaki K, Uchiyama T.
    Haematologica; 2007 Jun 04; 92(6):857-8. PubMed ID: 17550864
    [Abstract] [Full Text] [Related]

  • 13. The Cytokine Storm of Multicentric Castleman Disease.
    Fajgenbaum DC.
    Adv Exp Med Biol; 2024 Jun 04; 1448():459-467. PubMed ID: 39117833
    [Abstract] [Full Text] [Related]

  • 14. Sustained remission of severe Multicentric Castleman disease following multiagent chemotherapy and tocilizumab maintenance.
    Turcotte LM, Correll CK, Reed RC, Moertel CL.
    Pediatr Blood Cancer; 2014 Apr 04; 61(4):737-9. PubMed ID: 24019247
    [Abstract] [Full Text] [Related]

  • 15. [Pharmacological and clinical profile of anti-human IL-6 receptor antibody (tocilizumab, ACTEMRA), a novel therapeutic drug for Castleman's disease].
    Ohsugi Y, Tsuchimoto N.
    Nihon Yakurigaku Zasshi; 2005 Dec 04; 126(6):419-25. PubMed ID: 16462093
    [No Abstract] [Full Text] [Related]

  • 16. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.
    van Rhee F, Casper C, Voorhees PM, Fayad LE, van de Velde H, Vermeulen J, Qin X, Qi M, Tromp B, Kurzrock R.
    Oncotarget; 2015 Oct 06; 6(30):30408-19. PubMed ID: 26327301
    [Abstract] [Full Text] [Related]

  • 17. Successful treatment of autoimmune hemolytic anemia associated with multicentric Castleman disease by anti-interleukin-6 receptor antibody (tocilizumab) therapy.
    Yuzuriha A, Saitoh T, Koiso H, Mitsui T, Uchiumi H, Yokohama A, Handa H, Kojima M, Tsukamoto N, Karaswa M, Murakami H, Nojima Y.
    Acta Haematol; 2011 Oct 06; 126(3):147-50. PubMed ID: 21757886
    [Abstract] [Full Text] [Related]

  • 18. JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease.
    Patel M, Ikeda S, Pilat SR, Kurzrock R.
    JAMA Dermatol; 2017 May 01; 153(5):449-452. PubMed ID: 28241173
    [Abstract] [Full Text] [Related]

  • 19. Short-term efficacy of the IL6 receptor antibody tocilizumab in patients with HIV-associated multicentric Castleman disease: report of two cases.
    Nagao A, Nakazawa S, Hanabusa H.
    J Hematol Oncol; 2014 Jan 17; 7():10. PubMed ID: 24438824
    [Abstract] [Full Text] [Related]

  • 20. Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data.
    Morra DE, Pierson SK, Shilling D, Nemat S, Appiani C, Guilfoyle M, Tendler C, van Rhee F, Fajgenbaum DC.
    Br J Haematol; 2019 Jan 17; 184(2):232-241. PubMed ID: 30203839
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.